KLK3 and posterior cortical atrophy: In LOCATE, an open-label, prospective phase 4, multicenter study of 221 patients with PCa, 18F-fluciclovine PET/CT positivity rates were proportional to PSA concentrations: detection rates were 31% in patients with PSA levels 0–0.5 ng/ml, 50% in patients with PSA levels >0.5–1.0 ng/ml, and 66% in patients with PSA levels >1.0–2.0 ng/ml [31].